

One Step Morphine Test Strip (Urine) Package Insert

REF 1188-S

A rapid, one step test for the qualitative detection of Morphine, Opiates, and Heroin in

For professional in vitro diagnostic use only.

IINTERNIDED USE

The MOP One Step Morphine Test Strip (Urine) is a lateral flow chromatographic immunoassay for the detection of Morphine in human urine at the cut-off concentration of 300 ng/mL. This test will detect other related compounds, please refer to the Analytical Specificity table in this package insert

This assay provides only a qualitative, preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

SUMMARY

Opioid analgesics comprise a large group of substances, which control pain by depressing the central nervous system. Large doses of Morphine can produce higher tolerance levels and physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose.

The MOP One Step Morphine Test Strip (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Morphine in urine. The MOP One Step Morphine Test Strip (Urine) yields a positive result when Morphine in urine reaches 300 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

PRINCIPLE

The MOP One Step Morphine Test Strip (Urine) is an immunoassay based on the principle of competitive binding. Drugs, which may be present in the urine specimen, compete against the drug conjugate for binding sites on the antibody.

During testing, a urine specimen migrates upward by capillary action. Morphine, if present in the urine specimen below 300 ng/mL, will not saturate the binding sites of the antibody coated particles in the test strip. The antibody coated particles will then be captured by immobilized Morphine conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the Morphine level is at or above 300 ng/mL because it will saturate all the binding sites of anti-Morphine antibodies.

A drug-positive urine specimen will not generate a colored line in the test line region because of drug competition, while a drug-negative urine specimen or a specimen containing a drug concentration less than the cut-off will generate a line in the test line region. To serve as a procedural control, a colored line will always appear at the control line region indicating that the proper volume of specimen has been added and membrane wicking has occurred.

REAGENTS

The test strip contains mouse monoclonal anti-Morphine antibody-coupled particles and Morphineprotein conjugate. A goat antibody is employed in the control line system.

- · For professional in vitro diagnostic use only. Do not use after the expiration date.
- . The test strip should remain in the sealed pouch until use.
- · All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.
- · The used test strip should be discarded according to local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch either at room temperature or refrigerated (2-30°C). The test strip is stable through the expiration date printed on the sealed pouch. The test strip must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

Urine Assay

The urine specimen must be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For long-term storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed before testing

MATERIALS

Materials Provided


 Test strips Package insert

Materials Required But Not Provided

· Specimen collection container

Allow the test strip, urine specimen, and/or controls to reach room temperature (15-30°C)

- 1. Bring the pouch to room temperature before opening it. Remove the test strip from the sealed pouch and use it as soon as possible.
- 2. With arrows pointing toward the urine specimen, immerse the test strip vertically in the urine specimen for at least 10-15 seconds. Do not pass the maximum line (MAX) on the test strip when immersing the strip. See the illustration below.
- 3. Place the test strip on a non-absorbent flat surface, start the timer and wait for the colored line(s) to appear. Read results at 5 minutes. Do not interpret the result after 10 minutes.



INTERPRETATION OF RESULT

(Please refer to the illustration above)

NEGATIVE:* Two lines appear. One colored line should be in the control line region (C), and another apparent colored line should be in the test line region (T). This negative result indicates that the Morphine concentration is below the detectable level (300 ng/mL).

*NOTE: The shade of color in the test line region (T) may vary, but it should be considered negative whenever there is even a faint colored line.

POSITIVE: One colored line appears in the control line region (C). No line appears in the test line region (T). This positive result indicates that the Morphine concentration exceeds the detectable level (300 ng/mL).

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test strip. If the problem persists, discontinue using the lot immediately and contact vour local distributor

QUALITY CONTROL

A procedural control is included in the test. A colored line appearing in the control line region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit; however, it is recommended that positive and negative controls be tested as good laboratory testing practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

- 1. The MOP One Step Morphine Test Strip (Urine) provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.2
- 2. It is possible that technical or procedural errors, as well as other interfering substances in the urine specimen may cause erroneous results
- 3. Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- 4. Certain medications containing opiate derivatives may produce a positive result. Additionally, foods and tea containing poppy products (the origin of opiates) may also produce a positive result.
- 5. A positive result indicates presence of the drug or its metabolites but does not indicate level of intoxication, administration route or concentration in urine.
- 6. A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- 7. Test does not distinguish between drugs of abuse and certain medications

PERFORMANCE CHARACTERISTICS

A side-by-side comparison was conducted using the MOP One Step Morphine Test Strip (Urine) and a leading commercially available MOP rapid test. Testing was performed on 300 clinical specimens previously collected from subjects present for Drug Screen Testing. Ten percent of the specimens employed were either at -25% or +25% level of the cut-off concentration of 300 ng/mL Morphine. Presumptive positive results were confirmed by GC/MS. The following results

Method		Other MOI	Total Results			
MOP One Step	Results	Positive	Negative	Total Results		
Test Strip	Positive	150	0	150		
rest Strip	Negative	0	150	150		
Total Results % Agreement		150	150	300		
		>99%	>99%	>99%		

When compared to GC/MS at the cut-off of 300 ng/mL, the following results were tabulated:

Method		GC/	Total Results	
MOP One Step	Results	Positive	Negative	Total Results
Test Strip	Positive	141	9	150
rest Strip	Negative	0	150	150
Total Results		141	159	300
% Agreement		>99%	94%	97%

A drug-free urine pool was spiked with Morphine at the following concentrations: 0 ng/mL, 150 ng/mL, 225 ng/mL, 300 ng/mL, 375 ng/mL and 450 ng/mL. The result demonstrates > 99% accuracy at 50% above and 50% below the cut-off concentration. The data are summarized

Morphine	Percent of Cut-off	Cut-off n	Visual Result		
Concentration (ng/mL)	rereent of Cut-on		Negative	Positive	
0	0	30	30	0	
150	-50%	30	30	0	
225	-25%	30	25	5	
300	Cut-off	30	17	13	
375	+25%	30	1	29	
450	+50%	30	0	30	

Analytical Specificity

The following table lists compounds that are positively detected in urine by the MOP One Step Morphine Test Strip (Urine) at 5 minutes.

Compound	Concentration (ng/mL)	Compound	Concentration (ng/n
Codeine	300	Morphine 3-β-D-glucuronide	1,000
Ethylmorphine	6,250	Norcodeine	6,250
Hydrocodone	50,000	Normorphone	100,000
Hydromorphone	3,125	Oxycodone	30,000
Levorphanol	1,500	Oxymorphone	100,000
Thebaine	6,250	Procaine	15,000
Morphine	300	6-Monoacethylmorphine	400

A study was conducted at three physicians' offices by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical panel of coded specimens containing, according to GC/MS, no Morphine, 25% Morphine above and below the cut-off and 50% Morphine above and below the 300 ng/mL cut-off was provided to each site. The results are given below:

Morphine	n	Site A		Site B		Site C	
Concentration (ng/mL)	per Site	-	+	-	+	-	+
0	15	15	0	15	0	15	0
150	15	13	2	13	2	15	0
225	15	3	12	7	8	10	5
375	15	0	15	1	14	0	15
450	15	0	15	0	15	0	15

Effect of Urinary Specific Gravity

Fifteen urine specimens of normal, high, and low specific gravity ranges were spiked with 150 ng/mL and 450 ng/mL of Morphine. The MOP One Step Morphine Test Strip (Urine) was tested in duplicate. The results demonstrate that varying ranges of urinary specific gravity do not affect the test

Effect of Urinary pH

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with Morphine to 150 ng/mL and 450 ng/mL. The spiked, pH-adjusted urine was tested with the MOP One Step Morphine Test Strip (Urine) in duplicate. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drugfree urine or Morphine positive urine. The following compounds show no cross-reactivity when tested with the MOP One Step Morphine Test Strip (Urine) at a concentration of 100 μg/mL.

	Non Cross-React	ing Compounds	
4-Acetamidophenol	Creatinine	Loperamide	β-Phenylethylamine
Acetophenetidin	Deoxycorticosterone	Maprotiline	Phenylpropanolamin
N-Acetylprocainamide	Dextromethorphan	Meperidine	Prednisone
Acetylsalicylic acid	Diazepam	Meprobamate	D,L-Propanolol
Aminopyrine	Diclofenac	Methadone	D-Propoxyphene
Amitryptyline	Diflunisal	Methoxyphenamine	D-Pseudoephedrine
Amobarbital	Digoxin	(+) 3,4-Methylenedioxy-	Quinidine
Amoxicillin	Diphenhydramine	amphetamine	Quinine
Ampicillin	Doxylamine	(+) 3,4-Methylenedioxy-	Ranitidine
L-Ascorbic acid	Ecgonine hydrochloride	methamphetamine	Salicylic acid
D,L-Amphetamine	Ecgonine methylester	Nalidixic acid	Secobarbital
Apomorphine	(-)-ψ-Ephedrine	Nalorphine	Serotonin
Aspartame	Erythromycin	Naloxone	(5-Hydroxytyramine)
Atropine	β-Estradiol	Naltrexone	Sulfamethazine
Benzilic acid	Estrone-3-sulfate	Naproxen	Sulindac
Benzoic acid	Ethyl-p-aminobenzoate	Niacinamide	Temazepam
Benzoylecgonine	Fenoprofen	Nifedipine	Tetracycline
Benzphetamine	Furosemide	Norethindrone	Tetrahydrocortisone,
Bilirubin	Gentisic acid	D-Norpropoxyphene	3-Acetate
±) - Brompheniramine	Hemoglobin	Noscapine	Tetrahydrocortisone
Caffeine	Hydralazine	D,L-Octopamine	3-(β-D glucuronide)
Cannabidiol	Hydrochlorothiazide	Oxalic acid	Tetrahydrozoline
Chloralhydrate	Hydrocortisone	Oxazepam	Thiamine
Chloramphenicol	O-Hydroxyhippuric acid	Oxolinic acid	Thioridazine
Chlordiazepoxide	p-Hydroxy-	Oxymetazoline	D, L-Tyrosine
Chlorothiazide	methamphetamine	Papaverine	Tolbutamide
±) Chlorpheniramine	3-Hydroxytyramine	Penicillin-G	Triamterene
Chlorpromazine	Ibuprofen	Pentazocine	Trifluoperazine
Chlorquine	Imipramine	Pentobarbital	Trimethoprim
Cholesterol	Iproniazid	Perphenazine	Trimipramine
Clomipramine	(±) Isoproterenol	Phencyclidine	Tryptamine
Clonidine	Isox suprine	Phenelzine	D, L-Tryptophan
Cocaine hydrochloride	Ketamine	Phenobarbital	Tyramine
Cortisone	Ketoprofen	Phentermine	Uric acid
-) Cotinine	Labetalol	L-Phenylephrine	Verapamil
			Zomepirac

RIBLIOGRAPHY

Tietz NW. <u>Textbook of Clinical Chemistry.</u> W.B. Saunders Company. 1986; 1735 Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 2nd Ed. Biomedical Publ., Davis, CA. 1982; 488

3. Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986

Index of Symbols

1	Storage Temperature	3	Manufacturer	2	Do not reuse
LOT	Lot Code	EC REP	Authorized Representative	IVD	For in vitro diagnostic use
Σ	Expiration	\triangle	Caution, see instructions	REF	Catalog No.





61188-S Jan 2010